BrainsWay Ltd. (BWAY) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 47% of 52W Range • RSI-14 at 40.9 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 61/100 (C-) score, BWAY faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.95) or 200D SMA ($13.92) invalidates the momentum regime and cuts Target Base ($12.09) toward Bear Floor ($9.43).
BrainsWay Ltd. (BWAY) surged +4.93% to $11.93, trading at 47% of its 52-week range ($7.14 – $17.4). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental heal
BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announ
Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry TreatmentsBURLINGTON, Mass. and JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE)
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $19 price target.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced a strategic
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BWAY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BWAY. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, BrainsWay Ltd. (BWAY) ranks #190 by composite RQD confidence (61/100, grade C-) and #461 by equity capitalization ($478.7M). Within this direct 5-issuer industry benchmark cohort, BWAY leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. BWAY currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BWAY
ACTIVE
BrainsWay Ltd. | C- | 61/100 | — | — | — | +4.93% | $478.7M | Benchmark Subject |
| SSII SS Innovations International Inc. | D- | 39/100 | — | 46.0% | -18.5% | -2.46% | $477.2M | /ssii-vs-bway → |
| CERS Cerus Corporation | D- | 37/100 | — | — | -15.5% | +0.83% | $491.7M | /cers-vs-bway → |
| DCTH Delcath Systems Inc. | D+ | 57/100 | — | 86.2% | 0.8% | -1.48% | $508.0M | /dcth-vs-bway → |
| NPCE Neuropace Inc. | E | 30/100 | — | 77.2% | -23.0% | +0.62% | $446.6M | /npce-vs-bway → |
BrainsWay Ltd. (BWAY) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $478.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, BrainsWay Ltd. (NASDAQ: BWAY) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $11.93 (+4.93% 1D, market cap $478.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BWAY ranks #190 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), BWAY carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SSII (SS Innovations International Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M) and CERS (Cerus Corporation) posts a D- grade (37/100 RQD, P/E N/A, ROIC -15.5%, cap $491.7M). Among the 5-stock peer group, BWAY leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).
For BrainsWay Ltd. (BWAY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #190 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
BWAY last traded at $11.93 (+4.93% on volume of 121,745 shares), positioning the stock -7.88% below its 50-day simple moving average ($12.95) and -14.30% below its 200-day simple moving average ($13.92). Across its 52-week range of $7.14 to $17.40, BWAY sits at the 46.7% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($10.99 to $12.87).
Why BWAY Stock surged +4.93% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.